Skip to Content
01. Doctor Overview

Doctor Overview

A renowned expert on lung cancer and a leader in surgical therapies for thoracic cancers such as pleural mesothelioma, Dr. David Jablons is an Ada Distinguished Professor of Thoracic Oncology and Professor of Cardiothoracic Surgery at the University of California, San Francisco School of Medicine. He is also Chief of General Thoracic Surgery at the UCSF Medical Center.

After earning his medical degree from Albany Medical College of Union University, Dr. Jablons completed a surgical residency at Tufts-New England Medical Center and a Cardiothoracic Fellowship at Cornell University Medical Center. He has authored numerous articles and research papers and receives many requests to lecture about his lung cancer research at conferences and meetings around the world. Dr. Jablons leads research at the UCSF Thoracic Oncology Laboratory on the molecular biology and genomics of lung cancer.

02. Fast Facts

Doctor Fast Facts

Main Specialty: Thoracic Surgery

Other Interests & Specialties: General cardiac/thoracic surgery, carcinoid tumors, chest wall tumors, esophageal cancer, lung metastases, lung transplantation, lung volume reduction surgery, malignant mesothelioma, mediastinal masses, minimally invasive thoracic surgery, non-small cell lung cancer, robotic thoracic surgery, sarcomas, small cell lung cancer, video-assisted thoracoscopic surgery and early detection.

Certifications, Awards & Accolades: American Board of Thoracic Surgery Certification in Thoracic and Cardiac Surgery, Surgical Resident Teaching Award from the University of California, Thoracic Oncology Program affiliation, UCSF Helen Diller Family Comprehensive Cancer Center member

Education & Experience:

  • Residency in General Surgery at Tufts Medical Center
  • Fellowship in Thoracic Surgery New York Presbyterian Hospital – Cornell Campus
  • Internship at Naval Hospital
  • Medical Degree from Albany Medical College
03. Publications


Targeting YAP in malignant pleural mesotheliomaJournal of Cellular and Molecular Medicine. November 2017;21(11):2663-2676. doi: 10.1111/jcmm.13182

DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesotheliomaInternational Journal of Oncology. July 2017;51(1):91-103. doi: 10.3892/ijo.2017.4021

Cul4A overexpression associated with Gli1 expression in malignant pleural mesotheliomaJournal of Cellular and Molecular Medicine. October 2015;19(10):2385-96. doi: 10.1111/jcmm.12620

Drug development against the hippo pathway in mesotheliomaTranslational Lung Cancer Research. June 2017;6(3):335-342. doi: 10.21037/tlcr.2017.06.02

Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesotheliomaBiochemical and Biophysical Research Communications. April 2006;342(4):1228-32.

Wnt2 as a new therapeutic target in malignant pleural mesotheliomaInternational Journal of Cancer. November 2005;117(2):326-32.